ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements
Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.
Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.
Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.
Vaishali Pharma Limited announced the resignation of Mr. Bhaveshkumar Popatlal Upadhyay from the position of Non-Executive Independent Director, effective August 14, 2026.
Vaishali Pharma Ltd reported revenue from operations of ₹22.9 Cr (-3.4% YoY) and net profit of ₹1.5 Cr (+15.4% YoY) for Q1 FY27.
Vaishali Pharma Limited scheduled a board meeting for August 14, 2026, to approve the standalone and consolidated unaudited financial results for the quarter ended June 2026.
Vaishali Pharma declared postal ballot results for special resolutions. Resolutions for director re-appointments and remuneration were passed with overwhelming shareholder support.
Vaishali Pharma allotted shares via a Rs. 9.08 Crore preferential issue. This capital infusion increases total paid-up equity to 134,999,995 shares.
Vaishali Pharma allotted 45.38 lakh shares at Rs.20 each to Kesar Pharma, raising Rs.9.08 Cr. The capital increase is for a 26.95% stake swap.
Vaishali Pharma's Board approved increasing authorized share capital from ₹27 Cr to ₹29 Cr. The proposal requires member approval and MoA amendments.
Vaishali Pharma scheduled a board meeting for July 2, 2026. The board will consider fund raising via a preferential issue.
Vaishali Pharma issued a postal ballot notice for shareholder approval of director re-appointments and remuneration revisions. The e-voting period ends on July 3, 2026.
Vaishali Pharma Ltd reported revenue from operations of ₹26.9 Cr and net profit of ₹0.1 Cr for Q4 FY26.
Vaishali Pharma approved audited financial results for the year ended March 31, 2026. The board meeting concluded with the adoption of annual standalone and consolidated accounts.
Vaishali Pharma scheduled a board meeting for May 30, 2026, to approve audited financial results. The trading window remains closed until June 2, 2026.
Vaishali Pharma approved the five-year re-appointment of its Independent, Managing, and Whole-Time Directors. These leadership extensions ensure management continuity and strategic stability for shareholders.
Vaishali Pharma Limited clarified to the NSE that recent stock price fluctuations are purely market-driven. The company confirmed it has disclosed all material information under SEBI Regulation 30 and has no pending price-sensitive news. This response addresses an exchange surveillance query to ensure market transparency.
Vaishali Pharma Ltd reported net profit of ₹1.3 Cr (-7.1% YoY) for Q3 FY26.